Get the Stockscreener App
10.82
2.64%
-0.53
Gh Research Plc stock is traded at $10.82, with a volume of 47,621.
It is down -2.64% in the last 24 hours and down -22.78% over the past month.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
See More
Previous Close:
$11.35
Open:
$11.75
24h Volume:
47,621
Relative Volume:
0.11
Market Cap:
$690.99M
Revenue:
-
Net Income/Loss:
$-41.43M
P/E Ratio:
-13.70
EPS:
-0.79
Net Cash Flow:
$-39.97M
1W Performance:
+4.74%
1M Performance:
-22.78%
6M Performance:
+33.13%
1Y Performance:
+7.28%
1-Day Range:
$10.95
$11.75
1-Week Range:
$10.22
$11.75
52-Week Range:
$6.00
$20.50
Gh Research Plc Stock (GHRS) Company Profile
Compare GHRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GHRS
Gh Research Plc
|
10.96 | 690.99M | 0 | -41.43M | -39.97M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.30 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
685.15 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
578.42 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.21 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.40 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Gh Research Plc Stock (GHRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Feb-13-25 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-16-22 | Initiated | H.C. Wainwright | Buy |
| Jun-16-22 | Initiated | ROTH Capital | Buy |
Gh Research Plc Stock (GHRS) Latest News
Guggenheim starts GH Research at Buy, sees long-term upside potential - TipRanks
GH Research PLC (GHRS) Shares Rise Despite Market Challenges - The News Heater
How to Take Advantage of moves in (GHRS) - Stock Traders Daily
GH Research (NASDAQ:GHRS) Earns Outperform Rating from Analysts at Royal Bank of Canada - Defense World
Q1 Earnings Forecast for GH Research Issued By HC Wainwright - Defense World
RBC Capital Initiates Coverage of GH Research (GHRS) with Outperform Recommendation - Nasdaq
GH Research initiated with an Outperform at RBC Capital - TipRanks
GH Research PLC Reports 2024 Financial Results and Clinical Progress - TipRanks
H.C. Wainwright maintains $40 target on GH Research stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $40 target on GH Research stock - Investing.com
Postpartum Depression Pipeline Revealed in 2025 Forecast Report Featuring GH Research, Reunion Neuroscience, Lipocine, and Brii Biosciences - GlobeNewswire Inc.
Why GH Research PLC (GHRS) is Skyrocketing So Far in 2025 - MSN
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
GH Research PLC (GHRS): Among the Best Psychedelic Stocks to Buy in 2025 - Insider Monkey
GH Research (GHRS) to Release Quarterly Earnings on Thursday - MarketBeat
GH Research (NASDAQ:GHRS) Announces Quarterly Earnings Results - MarketBeat
H.C. Wainwright maintains buy on GH Research stock, $40 target - MSN
12 Best Psychedelic Stocks to Buy in 2025 - Insider Monkey
Psychedelic: GH Research, Compass Pathways report earnings results - Yahoo Finance
GH Research (NASDAQ:GHRS) Given New $32.00 Price Target at Stifel Nicolaus - MarketBeat
GH Research Reports Full Year 2024 Financial Results and Provides Business Updates - GlobeNewswire
Form F-3 GH Research PLC - StreetInsider.com
GH Research Reports 2024 Financial Results and Clinical Progress - TipRanks
Can GH Research's Depression Drug Change Treatment Paradigms? Phase 2b Shows Striking 57.5% Remission Rate - StockTitan
Stifel raises GH Research stock target to $32 on strong trial data - Investing.com
Stifel raises GH Research stock target to $32 on strong trial data By Investing.com - Investing.com South Africa
GH Research PLC (GHRS): Among the Best Performing Small Cap Stocks So Far In 2025 - Insider Monkey
Small-Cap Stocks Surge: GH Research, Society Pass and Reborn Coffee Lead Monday Gainers - HPBL
GHRS Stock Rallies 55% in a Week: Here's What You Should Know - MSN
Cantor Fitzgerald Forecasts GH Research FY2024 Earnings - Defense World
GH Research (NASDAQ:GHRS) Earns Overweight Rating from Analysts at Cantor Fitzgerald - MarketBeat
Cantor Fitzgerald Initiates Coverage of GH Research (GHRS) with Overweight Recommendation - MSN
Cantor Fitzgerald sets GH Research stock Overweight, $14 target By Investing.com - Investing.com Australia
Cantor Fitzgerald sets GH Research stock Overweight, $14 target - MSN
GH Research initiated with an Overweight at Cantor Fitzgerald - TipRanks
Cantor Fitzgerald Initiates GH Research at Overweight -February 13, 2025 at 07:35 am EST - Marketscreener.com
GH Research - The Pharma Letter
These 5 Health Care Stocks Saw The Sharpest Retail Interest Jump Last Week - NewsBreak
GH Research (NASDAQ:GHRS) Shares Gap UpStill a Buy? - MarketBeat
GH Research PLC's (NASDAQ:GHRS) Top Key Executive Florian Schonharting is the most upbeat insider, and their holdings increased by 31% last week - Yahoo Finance
Gh Research Plc Stock (GHRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):